Cancer drug combo studied in kids – but trial stopped early
NCT ID NCT04544995
First seen Jan 21, 2026 · Last updated Jun 16, 2026 · Updated 21 times
Summary
This early-stage study tested a combination of two drugs (niraparib and dostarlimab) in children and teens aged 6 months to 18 years whose solid tumors had come back or did not respond to treatment. The main goals were to find safe doses and see how the drugs worked in the body. The study was terminated, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Birmingham, B4 6NH, United Kingdom
-
GSK Investigational Site
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.